Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma.
Tovoli F, Pallotta DP, Vivaldi C, Campani C, Federico P, Palloni A, Dalbeni A, Soldà C, Lani L, Svegliati-Baroni G, Garajova I, Ielasi L, De Lorenzo S, Granito A, Stefanini B, Masi G, Marra F, Lonardi S, Brandi G, Daniele B, Auriemma A, Schiadà L, Chen R, Piscaglia F; ARTE study group. Tovoli F, et al. Among authors: ielasi l. Dig Liver Dis. 2024 Dec;56(12):2079-2084. doi: 10.1016/j.dld.2024.07.035. Epub 2024 Aug 20. Dig Liver Dis. 2024. PMID: 39168753 Free article.
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy.
Ielasi L, Stefanini B, Conti F, Tonnini M, Tortora R, Magini G, Sacco R, Pressiani T, Trevisani F, Foschi FG, Piscaglia F, Granito A, Tovoli F. Ielasi L, et al. Curr Oncol. 2024 Jan 19;31(1):547-557. doi: 10.3390/curroncol31010038. Curr Oncol. 2024. PMID: 38275831 Free PMC article.
Donafenib in hepatocellular carcinoma.
Chen R, Ielasi L, di Carlo A, Tovoli F. Chen R, et al. Among authors: ielasi l. Drugs Today (Barc). 2023 Feb;59(2):83-90. doi: 10.1358/dot.2023.59.2.3507751. Drugs Today (Barc). 2023. PMID: 36811408 Review.
TKIs in combination with immunotherapy for hepatocellular carcinoma.
Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F, Granito A. Stefanini B, et al. Among authors: ielasi l. Expert Rev Anticancer Ther. 2023 Mar;23(3):279-291. doi: 10.1080/14737140.2023.2181162. Epub 2023 Feb 26. Expert Rev Anticancer Ther. 2023. PMID: 36794716 Review.
27 results